Vázquez-Blomquist, Dania
Leenstra, Sieger
van der Kaaij, Mariëlle
Villarreal, Adelaida
Bello-Rivero, Iraldo
Funding for this research was provided by:
UICC International Cancer Technology Transfer Fellowship (ICR/2014/328167)
Article History
Received: 24 December 2019
Accepted: 20 June 2020
First Online: 30 June 2020
Compliance with ethical standards
:
: DVB, AV and IBR are employees of the Center for Genetic Engineering and Biotechnology, in Havana where HeberFERON is produced. The authors have no competing interests.
: The research protocol and patient informed consent form that specified the use of patient material for research on brain tumors neurology, neurosurgery and pathology was approved by the Medical Ethics Review Committee (MERC; METC in Dutch) of ErasmusMC (MEC 221.520/2002/262). The research protocol was conducted under the responsibility of the ErasmusMC departments of Neurology, Neurosurgery and Pathology.
: Primary glioblastoma cell cultures were derived from tumors of operated patients from the Erasmus Medical Center Rotterdam, The Netherlands. Prior to surgery, patients sign informed consent. All authors consent for publication of the results included in this article.